Exclusive Interview with John Glick, MD

Tom Dilling, Alec Schwartz
University of Pennsylvania Cancer Center
Ultima Vez Modificado: 20 de mayo del 1996

Dr. Bunn: There are six new drugs which have been approved or are about to be approved for treating lung cancer and they're probably all six of them better than drugs which we've had in the past, and I think they will improve survival for patients with lung cancer.

I guess the second point is that the patients who have "earlier-stage" [lung cancer], if you give them chemotherapy with radiation or with surgery or all three together, it is providing better survival than what we had in the past with just surgery alone.

And the last thing you can tell your people is: Don't smoke!

OncoLink: Just to reiterate again for all our listeners and readers out there who were not at this talk....

Dr. Bunn: They're not here? I thought they were all here!

  • laugh
  • OncoLink: Yes, well....

    What were those six new drugs which you see as on the forefront?

    Dr. Bunn: There's two taxanes, paclitaxel and docetaxel, which some people call taxol and taxotere; there's two topoisomerase I inhibitors, irinotecan and topotecan; and then there's navelbine and gemcitabine (Gemzar®).

  • Keywords

    Click on any of these terms for more related articles

    Blogs

    In Celebration of Eric Ott
    by Bob Riter
    August 17, 2015

    Related News

    AACR: Conference Offers Look at Cancer Drugs in Pipeline

    Aug 31, 2015

    International conference presentations include leukemia drug screening, olaparib, cediranib


    RAD51 Mutations Confer Moderate Risk of Ovarian Cancer

    Aug 16, 2015

    RAD51C and RAD51D deleterious mutations linked to increased risk of epithelial ovarian cancer


    But does not completely offset risk conferred by family history of late-onset breast cancer

    Oct 14, 2010

    But does not completely offset risk conferred by family history of late-onset breast cancer